Navigation Links
Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results
Date:6/2/2010

WALTHAM, Mass., June 2 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it will disclose its financial results for the fourth quarter and fiscal year 2010, on Wednesday, June 9th, 2010, before the market opens.  The Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on the same day at 10:00 a.m. EDT, to discuss the financial results and provide a quarterly update on the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at www.repligen.com.  If you are unable to access the webcast, you may listen live by calling (866) 783-2140 for domestic calls and (857) 350-1599 for international calls. Participants must provide the following passcode: 60999264.  For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call on Repligen's website www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders.
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 Offering a complete line ... Entris Balance promotion . The Sartorius Entris Balance is ... high accuracy, and easy-to-maintain balance entry level balance. , ... was designed to help customer’s bridge the gap between ... that is very durable. Sartorius is the second biggest ...
(Date:11/21/2014)... November 20, 2014 The ... Chassis, Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, ... (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast ... market drivers, threats, opportunities, and challenges. , ... figures spread through 185 pages and in-depth ...
(Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... Wis. - Wisconsin's biobased industries could become a model ... are made, government and industry officials said at a leadership ... a summit to discuss Wisconsin's forest and agricultural industry and ... issues affecting expansion. Representatives from the U.S. Department of ...
... Being part of the more than 18,000 people who ... has not only become a worldwide phenomenon but its also becoming ... how rock n roll became mainstream in the 1960s. Though most ... on the Sunday night Ed Sullivan Show was a statement that ...
... What are you doing to become a better husband or ... not trying to turn my e-mail into a confessional. I've ... to folks who have been making that relationship work, it's ... and acceptance. Sounds like some idealized family. , ,"Oh great!" ...
Cached Biology Technology:Wisconsins biobased industries could be world leader 2Wisconsins biobased industries could be world leader 3Biotech phenomenon becoming mainstream in world economy 2Biotech phenomenon becoming mainstream in world economy 3Biotech phenomenon becoming mainstream in world economy 4Biotech phenomenon becoming mainstream in world economy 5Taking your work home 2Taking your work home 3
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... leaders do not immediately engage in a race against time ... not survive the global warming and acidification predicted for later ... marine scientists from around the world in a major new ... vital that the public understands that the lack of sustainability ...
... the winners of its student travel award to attend ... International Biophysics Congress in Long Beach, California, February 2-6, ... based on scientific merit, with priority given to those ... Each awardee receives a travel grant and will be ...
... Ore. December 21, 2007. In the early 1990s, federal ... Forest Plan. Part of that task involved an inventory ... to be associated with old-growth forests. Debates arose among the ... how best to carry it out. The recently published Conservation ...
Cached Biology News:Major study concludes that global warming is killing off coral 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
... Rabbit polyclonal to Taura Syndrome ... for all tested applications). ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN ... corresponding to N terminal amino ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: